A new medtech-pharma collaboration has its eye on catching retinal diseases as early as possible and staving them off with precise, personalized treatments.

一项新的medtech制药合作计划着眼于尽早发现视网膜疾病，并通过精确、个性化的治疗来预防视网膜疾病。

Zeiss Medical Technology and Boehringer Ingelheim provided a bird’s-eye view of their partnership Monday. The overarching aim of the collab is to spot and treat eye diseases before permanent damage sets in, which is currently a risk for more than 300 million people around the world—a number that’s expected to keep growing alongside aging populations and increasing gaps in health equity, according to the companies’ joint announcement..

周一，蔡司医疗科技公司和勃林格殷格翰公司对他们的合作关系进行了鸟瞰。这项合作的首要目标是在永久性损害发生之前发现和治疗眼部疾病，目前全球有3亿多人面临这种风险，根据两家公司的联合声明，预计这一数字将随着人口老龄化和健康公平差距的扩大而持续增长。。

“Our partnership with Zeiss Medical Technology will allow us to develop precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs,” said Ulrike Graefe-Mody, Ph.D., Boehringer’s head of retinal health.

勃林格视网膜健康负责人乌尔里克·格雷夫·莫迪博士说：“我们与蔡司医疗技术的合作将使我们能够开发精确疗法，在正确的时间为正确的患者提供正确的治疗，通过在不可逆的损害发生之前进行干预来预防视力丧失。”。

Financial terms of the team-up weren’t disclosed..

该团队的财务条款未披露。。

The partnership will build on both Zeiss and Boehringer’s expertise in the realm of ophthalmology, as well as their respective strengths in technological and therapeutic development.

该合作关系将建立在蔡司和勃林格在眼科领域的专业知识以及他们各自在技术和治疗发展方面的优势之上。

Zeiss, for its part, will task its artificial intelligence algorithms with sifting through massive sets of imaging data on its cloud platform, which takes in information from a variety of diagnostic and therapeutic devices. The AI will then analyze those scans to look for early markers of retinal diseases..

蔡司（Zeiss）将在其云平台上筛选大量成像数据集，从而使用人工智能算法，该平台接收来自各种诊断和治疗设备的信息。AI随后将分析这些扫描，以寻找视网膜疾病的早期标志物。。

With Boehringer’s help, those findings can then be used to develop not only diagnostic and predictive tools to catch the conditions at the point of care but also new therapeutics that’ll use the early disease markers as a starting point to target disease pathways.

在勃林格（Boehringer）的帮助下，这些发现不仅可以用于开发诊断和预测工具，以捕捉护理点的病情，还可以用于开发新的治疗方法，将早期疾病标志物作为靶向疾病途径的起点。

“Enabled by our Zeiss Medical Ecosystem and the platform’s ability to aggregate massive data sets for analysis, we’re strongly positioned to establish new partnerships in pursuit of research yet to be investigated, to accelerate access to future technologies and markets, and to help clinicians provide earlier detection and more personalized and precise care for their patients,” Euan Thomson, Ph.D., head of Zeiss’ ophthalmology strategic business unit and digital business unit, said in the announcement..

“凭借蔡司医疗生态系统和平台收集大量数据集进行分析的能力，我们有能力建立新的合作伙伴关系，以进行尚未调查的研究，加速进入未来的技术和市场，并帮助临床医生为患者提供早期检测和更个性化、更精确的护理，”Euan蔡司眼科战略业务部门和数字业务部门负责人汤姆森博士在公告中表示。。

Boehringer has been developing treatments for ophthalmological diseases since 2013 when the German pharma first identified its own potential in treating retinal conditions associated with diabetes.

自2013年德国制药公司首次发现自己在治疗糖尿病相关视网膜疾病方面的潜力以来，勃林格一直在开发眼科疾病的治疗方法。

In the decade since, helped along by the creation of a dedicated retinal health department in 2019, it has expanded its focus beyond diabetic retinopathy and diabetic macular ischemia. Other key therapy areas within the department now include wet age-related macular degeneration, geographic atrophy and Stargardt disease..

自2019年成立专门的视网膜健康部门以来，在这十年的帮助下，它将重点扩展到了糖尿病视网膜病变和糖尿病性黄斑缺血。该部门的其他关键治疗领域现在包括湿性年龄相关性黄斑变性，地理萎缩和Stargardt病。。

That work has included a handful of partnerships, including one with intravitreal drug delivery tech maker Inflammasome Therapeutics in 2019 and another with CDR-Life in 2020 to develop antibody fragment-based therapeutics for geographic atrophy.

这项工作包括一些合作伙伴关系，其中一个是2019年与玻璃体内药物输送技术制造商Inflammasome Therapeutics合作，另一个是2020年与CDR Life合作，开发基于抗体片段的地理萎缩疗法。

Zeiss’ own experience in ophthalmology dates even further back, to when the company began churning out eyeglass lenses in the early 1900s, followed by a string of ophthalmic instruments throughout the 20th century. In 1996, Zeiss was responsible for the commercial debut of optical coherence tomography, a form of radiation-free imaging designed to spot vision-threatening conditions in the retina, which was last month named the winner of the annual Lasker-DeBakey Clinical Medical Research Award..

蔡司自己在眼科方面的经验甚至可以追溯到20世纪初，当时该公司开始大量生产眼镜镜片，随后在整个20世纪生产了一系列眼科仪器。1996年，蔡司（Zeiss）负责光学相干断层扫描（optical coherence tomography）的商业首次亮相，这是一种无辐射成像形式，旨在发现视网膜中威胁视力的疾病，上月被评为年度拉斯克·德巴基（Lasker DeBakey）临床医学研究奖（Clinical Medical Research Award）的得主。。